Management of metastatic HER2-positive breast cancer: Where are we and where do we go from here?

Cesar A ugusto Santa-Maria, Lauren Nye, Martin B. Mutonga, Sarika Jain, William J. Gradishar

Research output: Contribution to journalArticle

26 Scopus citations

Abstract

This review will summarize the current standard of care; key issues that arise when treating patients with HER2-positive disease; and developments in novel therapeutics, including small-molecule inhibitors, nanoparticles, immunotherapy, and agents targeting resistance pathways.

Original languageEnglish (US)
JournalONCOLOGY (United States)
Volume30
Issue number2
StatePublished - Feb 15 2016

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Management of metastatic HER2-positive breast cancer: Where are we and where do we go from here?'. Together they form a unique fingerprint.

  • Cite this